Tilray's Stock Struggles Despite Regulatory Progress
Shares of Tilray Brands (TLRY) initially surged on positive regulatory developments regarding U.S. cannabis rescheduling but have since declined sharply to near their 52-week low. The company saw a short-lived rally at the end of last year, with its stock peaking around $23 before dropping below $5 today. While federal reclassification from Schedule I to III for certain marijuana products was seen as progress, investors remain skeptical about Tilray's ability to capitalize on it. Tilray’s Q4 FY 2026 financial results showed modest revenue growth driven largely by the acquisition of BrewDog assets in its beverage segment. However, excluding this one-time boost, core business performance remained weak with a decline in beverage sales and overall flat total revenue. The company also reported an improved net loss per share compared to last year due primarily to impairment charges recorded during that period. Looking ahead, there is potential for broader rescheduling of cannabis products including recreational use, but no guarantees exist regarding regulatory changes or market success.
Tickers: $TLRY
Topics: cannabis industry company performance regulatory changes